Logo image of NVCR

NOVOCURE LTD (NVCR) Stock Fundamental Analysis

NASDAQ:NVCR - JE00BYSS4X48 - Common Stock

12.43 USD
+0.52 (+4.37%)
Last: 8/22/2025, 8:27:46 PM
12.42 USD
-0.01 (-0.08%)
After Hours: 8/22/2025, 8:27:46 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NVCR. NVCR was compared to 187 industry peers in the Health Care Equipment & Supplies industry. NVCR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NVCR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

NVCR had negative earnings in the past year.
In the past year NVCR has reported a negative cash flow from operations.
In the past 5 years NVCR reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NVCR reported negative operating cash flow in multiple years.
NVCR Yearly Net Income VS EBIT VS OCF VS FCFNVCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

NVCR has a Return On Assets (-13.15%) which is comparable to the rest of the industry.
With a Return On Equity value of -45.36%, NVCR perfoms like the industry average, outperforming 51.34% of the companies in the same industry.
Industry RankSector Rank
ROA -13.15%
ROE -45.36%
ROIC N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
NVCR Yearly ROA, ROE, ROICNVCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

NVCR has a Gross Margin of 77.16%. This is amongst the best in the industry. NVCR outperforms 90.37% of its industry peers.
In the last couple of years the Gross Margin of NVCR has remained more or less at the same level.
NVCR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 77.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
NVCR Yearly Profit, Operating, Gross MarginsNVCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVCR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NVCR has more shares outstanding
Compared to 1 year ago, NVCR has a worse debt to assets ratio.
NVCR Yearly Shares OutstandingNVCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NVCR Yearly Total Debt VS Total AssetsNVCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -0.04, we must say that NVCR is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.04, NVCR perfoms like the industry average, outperforming 46.52% of the companies in the same industry.
A Debt/Equity ratio of 1.81 is on the high side and indicates that NVCR has dependencies on debt financing.
With a Debt to Equity ratio value of 1.81, NVCR is not doing good in the industry: 85.56% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Altman-Z -0.04
ROIC/WACCN/A
WACC6.53%
NVCR Yearly LT Debt VS Equity VS FCFNVCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

NVCR has a Current Ratio of 1.47. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.
NVCR's Current ratio of 1.47 is on the low side compared to the rest of the industry. NVCR is outperformed by 76.47% of its industry peers.
NVCR has a Quick Ratio of 1.41. This is a normal value and indicates that NVCR is financially healthy and should not expect problems in meeting its short term obligations.
NVCR has a Quick ratio of 1.41. This is in the lower half of the industry: NVCR underperforms 62.03% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.41
NVCR Yearly Current Assets VS Current LiabilitesNVCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

NVCR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.27%.
The Revenue has grown by 14.59% in the past year. This is quite good.
The Revenue has been growing by 11.49% on average over the past years. This is quite good.
EPS 1Y (TTM)1.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.13%
Revenue 1Y (TTM)14.59%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%5.62%

3.2 Future

NVCR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.33% yearly.
The Revenue is expected to grow by 19.05% on average over the next years. This is quite good.
EPS Next Y-7.24%
EPS Next 2Y-8.1%
EPS Next 3Y2.68%
EPS Next 5Y20.33%
Revenue Next Year5.14%
Revenue Next 2Y6.24%
Revenue Next 3Y9.86%
Revenue Next 5Y19.05%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NVCR Yearly Revenue VS EstimatesNVCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NVCR Yearly EPS VS EstimatesNVCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NVCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NVCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCR Price Earnings VS Forward Price EarningsNVCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCR Per share dataNVCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.1%
EPS Next 3Y2.68%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NOVOCURE LTD

NASDAQ:NVCR (8/22/2025, 8:27:46 PM)

After market: 12.42 -0.01 (-0.08%)

12.43

+0.52 (+4.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-24 2025-07-24/bmo
Earnings (Next)N/A N/A
Inst Owners79.37%
Inst Owner Change-0.64%
Ins Owners2.75%
Ins Owner Change2.33%
Market Cap1.39B
Analysts80
Price Target28.05 (125.66%)
Short Float %5.19%
Short Ratio3.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.69%
Min EPS beat(2)-73.92%
Max EPS beat(2)34.54%
EPS beat(4)3
Avg EPS beat(4)1.12%
Min EPS beat(4)-73.92%
Max EPS beat(4)34.54%
EPS beat(8)6
Avg EPS beat(8)5.58%
EPS beat(12)7
Avg EPS beat(12)-5.98%
EPS beat(16)8
Avg EPS beat(16)-115.75%
Revenue beat(2)2
Avg Revenue beat(2)1.92%
Min Revenue beat(2)0.18%
Max Revenue beat(2)3.65%
Revenue beat(4)4
Avg Revenue beat(4)4.5%
Min Revenue beat(4)0.18%
Max Revenue beat(4)8.53%
Revenue beat(8)5
Avg Revenue beat(8)2.21%
Revenue beat(12)6
Avg Revenue beat(12)0.92%
Revenue beat(16)7
Avg Revenue beat(16)-0.51%
PT rev (1m)-17.5%
PT rev (3m)-17.5%
EPS NQ rev (1m)1.25%
EPS NQ rev (3m)1.63%
EPS NY rev (1m)0%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)0.26%
Revenue NQ rev (3m)0.22%
Revenue NY rev (1m)0.67%
Revenue NY rev (3m)0.56%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.24
P/FCF N/A
P/OCF N/A
P/B 3.84
P/tB 3.84
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-1.82
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS5.56
BVpS3.24
TBVpS3.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.15%
ROE -45.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 77.16%
FCFM N/A
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
F-Score5
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 1.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 354.89%
Cap/Sales 6.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.41
Altman-Z -0.04
F-Score5
WACC6.53%
ROIC/WACCN/A
Cap/Depr(3y)276.52%
Cap/Depr(5y)245.8%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.13%
EPS Next Y-7.24%
EPS Next 2Y-8.1%
EPS Next 3Y2.68%
EPS Next 5Y20.33%
Revenue 1Y (TTM)14.59%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%5.62%
Revenue Next Year5.14%
Revenue Next 2Y6.24%
Revenue Next 3Y9.86%
Revenue Next 5Y19.05%
EBIT growth 1Y22.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.72%
EBIT Next 3Y28.27%
EBIT Next 5Y42.57%
FCF growth 1Y-1464.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-271.61%
OCF growth 3YN/A
OCF growth 5YN/A